Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric...
March 17, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx...
March 12, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric...
February 27, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal...
February 17, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric...
February 10, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal...
February 05, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics Welcomes New Members of the Board of Directors

PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of...
February 03, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch

PARAMUS, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal...
February 02, 2026 08:30 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”

PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization...
January 30, 2026 08:00 ET | Source: Polaryx Therapeutics, Inc.

Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq

PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization...